
Importance of Rebates and Future of Biosimilar Market | AMCP Nexus 2024
An optimistic outlook on the future of the biosimilar market driving down pharmaceutical drug spend.
In this discussion, Javier Gonzalez, Pharm.D., chief growth and commercial officer of Abarca, highlights the critical role of rebates in maintaining affordable health plan premiums and accessibility of specialty drugs.
“A lot of people say that the biosimilar space is at risk - I don't believe that,” Gonzalez said. “I think it will continue to be one of the main drivers of lowering our overall pharmaceutical drug spend over the next five to 10 years.”
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.

















































